ARQULE INC
ARQULE INC (ARQL): 5 pipeline candidates · ~40 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
39.8 months
D/E 0.18 · 0% dilution
Lead: Phase 3
5 candidates
N/A
N/A
A transparent, data-derived signal for ARQULE INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$42.2M
Quarterly Burn
$9.2M
Runway
39.8 mo
Revenue
$208K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| arq 531 | Phase 1 |
| arq 751 | Phase 1 |
| arq 761 | Phase 1/Phase 2 |
| derazantinib | Phase 3 |
| miransertib | Phase 1/Phase 2 |
Frequently asked questions
How many drug candidates are in ARQULE INC's pipeline?
ARQULE INC (ARQL) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ARQULE INC's lead drug candidate?
ARQULE INC's most advanced tracked candidate is arq 531 (Phase 1) for B-cell malignancies.
What is ARQULE INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ARQULE INC has approximately 39.8 months of cash runway.
Who is the CEO of ARQULE INC?
To Our Stockholders is the chief executive officer of ARQULE INC (ARQL).
Get the full picture on ARQULE INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.